Biogen Appoints Mark Hernon as SVP, Chief Information Officer

12/4/17

Mark Hernon

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4.

In his new role, Mr. Hernon will lead the global information technology (IT) organization and be responsible for accelerating and supporting Biogen’s operations through delivery of innovative technology capabilities, systems, and tools that align with Biogen’s corporate strategy. Mr. Hernon joins Biogen with more than 30 years of experience in IT and strategic leadership. In recent years with Takeda Pharmaceuticals, he was the Regional CIO for the Americas and Global Head of R&D, QA and HR Systems, as well as VP of Operations for the Cambridge, MA site. He was most recently the Global Head of R&D Site Strategy and Operations, where he led the global transformation of Takeda’s R&D footprint.

“With Mark’s years in industry successfully leading global IT and operations functions, we are extremely pleased to have him join us at Biogen,” said Ms. Alexander. “His experience and leadership together with our existing excellent Biogen IT organization will allow Biogen to continue creating and harnessing data and information to pioneer new developments in neuroscience.”

Prior to his role with Takeda, Mr. Hernon spent 12 years with Millennial Pharmaceuticals as CIO and VP Operations, leading strategic initiatives to streamline the organization, aligning with the business, and managing the group’s transition through the acquisition by Takeda.

“I am excited at the prospect of leading a team of talented and dedicated individuals focused on enabling Biogen’s strategy through the smart application of technology,” said Mr. Hernon.

Mr. Hernon holds a BS and MS in Industrial and Management Engineering from Rensselaer Polytechnic Institute, and an MBA from the Lally School of Management at Rensselaer Polytechnic Institute.

About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.